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Abstract
The molecular mechanisms leading to aryl hydrocarbon receptor interacting protein (AIP) mutation-induced aggressive,
young-onset growth hormone-secreting pituitary tumors are not fully understood. In this study, we have identiﬁed that AIP-
mutation-positive tumors are inﬁltrated by a large number of macrophages compared to sporadic tumors. Tissue from
pituitary-speciﬁc Aip-knockout (AipFlox/Flox;Hesx1Cre/+) mice recapitulated this phenotype. Our human pituitary tumor
transcriptome data revealed the “epithelial-to-mesenchymal transition (EMT) pathway” as one of the most signiﬁcantly
altered pathways in AIPpos tumors. Our in vitro data suggest that bone marrow-derived macrophage-conditioned media
induces more prominent EMT-like phenotype and enhanced migratory and invasive properties in Aip-knockdown
somatomammotroph cells compared to non-targeting controls. We identiﬁed that tumor-derived cytokine CCL5 is
upregulated in AIP-mutation-positive human adenomas. Aip-knockdown GH3 cell-conditioned media increases macrophage
migration, which is inhibited by the CCL5/CCR5 antagonist maraviroc. Our results suggest that a crosstalk between the
tumor and its microenvironment plays a key role in the invasive nature of AIP-mutation-positive tumors and the CCL5/
CCR5 pathway is a novel potential therapeutic target.
Introduction
Heterozygous mutations in the aryl hydrocarbon receptor
interacting protein (AIP) gene are present in about ﬁfth of
both familial isolated pituitary adenoma and childhood-
onset sporadic somatotroph adenomas [1]. Patients with
germline AIP mutations (AIPpos) have distinct clinical
features, such as young age at diagnosis, large, invasive,
sparsely-granulated adenomas with poor response to
somatostatin analogs [1–6]. Identiﬁcation of factors and
molecular pathways leading to this aggressive phenotype
are of particular importance to predict tumor behavior and
identify novel therapeutic targets.
Crosstalk between tumor cells and components of the
tumor microenvironment plays a key role in tumor invasion
[7–10]. The tumor microenvironment includes immune
cells, ﬁbroblasts, endothelial cells, extracellular matrix, and
numerous secreted soluble factors such as cytokines, alto-
gether representing a dynamic autocrine–paracrine interac-
tion network that inﬂuences tumor behavior. Relatively
sparse data are available on the tumor microenvironment of
pituitary adenomas. Previous studies found low level of
macrophage [11] or lymphocyte [12] inﬁltration, while a
more recent study showed that the presence of hemato-
poietic CD45+ cells was associated with poor clinical
outcome [13] or invasiveness in sparsely granulated soma-
totroph adenomas [14]. Understanding interactions between
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tumor cells and the tumor microenvironment may therefore
provide novel therapeutic targets.
Our observation of increased macrophage inﬁltration in
AIPpos tumors compared to sporadic somatotrophinomas,
combined with gene expression proﬁling of freshly frozen
AIPpos samples indicating altered tumor microenvironment,
prompted us to study the invasive behavior of AIPpos tumors
in terms of the microenvironment. We found that the tumor-
derived cytokine CCL5 is upregulated in AIP-mutation-posi-
tive human adenomas. The pituitary-speciﬁc Aip-knockout
mouse (AipFlox/Flox;Hesx1Cre/+) show increased macrophage
content, similar to the human AIPpos tumors. In our
in vitro experiments, supernatant of a stable Aip-knockdown
somatomammotroph cell line stimulated macrophage migra-
tion via CCL5/CCR5 pathway, while macrophage-derived
factors lead to epithelial-to-mesenchymal transition
(EMT), increased migration, and invasion in pituitary
somatotroph cells.
Results
Analysis of the components of the tumor
microenvironment in AIPpos tumors
To understand the tumor microenvironment of AIPpos
tumors, we evaluated expression of several key components
of the tumor microenvironment using speciﬁc molecular
markers for macrophages (CD68), T-reg cells (FOXP3),
cytotoxic T cells (CD8), and memory T cells (CD45RO).
Immunostaining with CD68 showed a remarkable increase
in the presence of CD68-positive cells in AIPpos tumors
compared to sporadic adenomas (P= 0.01) or normal
pituitaries (P= 0.001) (Fig. 1a). AIPpos tumors also
expressed a signiﬁcantly higher number of FOXP3+ T-reg
cells compared to sporadic adenomas (P= 0.02) or normal
tissues (P= 0.01) (Fig. 1b). No signiﬁcant differences were
found in cytotoxic (CD8) or memory T cell (CD45RO)
content (Fig. S1A, B).
EMT signatures in AIPpos tumors
Microarray gene expression proﬁling of normal pituitary
and familial or sporadic growth hormone (GH)-secreting
tumors (n= 15) identiﬁed several signiﬁcantly altered
pathways (Table S1). There were 3,025 differentially
expressed genes for AIPpos vs. normal pituitaries and 1,564
differentially expressed genes for sporadic tumors vs. nor-
mal pituitaries. The most signiﬁcantly altered canonical
pathways are shown in Fig. S2. The “Regulation of the
Epithelial-Mesenchymal Transition Pathway” was one of
the most signiﬁcantly altered pathways (47 genes with 16
upregulated and 31 downregulated) in AIPpos GH tumors
compared to sporadic adenomas (Table 1). Six EMT genes
(CDH1, CTNNB1, ESRP1, EPCAM, PERP, and ZEB1)
were selected for further validation (Table S2).
Fig. 1 Alterations of the components of the tumor microenvironment
in AIPpos tumors. Immunohistochemical analyses of CD68 and
FOXP3 in AIP-mutation-positive human somatotroph adenomas
(AIPpos), sporadic somatotroph adenomas (Sp GH), and normal
pituitaries. Graphs on the left are showing the percentage of CD68 (a)
and FOXP3 (b) positive cells per high-power magniﬁcation ﬁeld,
counted on 3–5 random ﬁelds at ×400. Plotted data were expressed as
mean ± SEM. Statistical analysis was performed using Kruskal–Wallis
test followed by Conover–Inman test for individual comparisons;
signiﬁcance between groups are marked as *, <0.05, ***, <0.001.
Representative images (right panels) show more CD68 (macrophages)
and FOXP3-positive (T-reg) cells in AIPpos tumors compared to
sporadic somatotroph adenomas. Analyzed number of samples for
normal pituitary, AIPpos tumors and sporadic GH tumors, respec-
tively, are as follows: CD68 (n= 9, 9, and 17) and FOXP3 (n= 11, 9,
and 17). All images are ×200 magniﬁcation and scale bar= 100 µm
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Table 1 Forty-seven known EMT-related genes in AIPpos somatotroph adenomas
Symbol Entrez gene name Affymetrix Fold change
ADAM17 ADAM metallopeptidase domain 17 205746_s_at 2.32
AKT3 v-akt murine thymoma viral oncogene homolog 3 242876_at −2.92
APC adenomatous polyposis coli 203527_s_at 2.80
BRAF B-Raf proto-oncogene, serine/threonine kinase 206044_s_at −3.90
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 201131_s_at −27.00
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 203440_at −17.74
CLDN3 claudin 3 203954_x_at −3.14
CTNNB1 catenin (cadherin-associated protein), beta-1, 88 kDa 223679_at −4.07
EGFR epidermal growth factor receptor 224999_at −5.65
EPCAM epithelial cell adhesion molecule 201839_s_at −2.42
ESRP1 epithelial splicing regulatory protein 1 225846_at −32.31
ESRP2 epithelial splicing regulatory protein 2 219395_at −5.92
FGF13 ﬁbroblast growth factor 13 205110_s_at −7.93
FGFR1 ﬁbroblast growth factor receptor 1 222164_at −4.63
FGFR2 ﬁbroblast growth factor receptor 2 203638_s_at −4.64
FGFR3 ﬁbroblast growth factor receptor 3 204379_s_at −9.55
FZD3 frizzled class receptor 3 239082_at −7.35
FZD5 frizzled class receptor 5 221245_s_at −3.71
FZD7 frizzled class receptor 7 203706_s_at −15.41
GSK3B glycogen synthase kinase 3 beta 226183_at 2.89
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 209960_at −4.20
HRAS Harvey rat sarcoma viral oncogene homolog 212983_at −2.11
JAG2 jagged 2 32137_at −2.97
JAK1 Janus kinase 1 239695_at −4.41
LEF1 lymphoid enhancer-binding factor 1 221558_s_at 3.57
LOX lysyl oxidase 215446_s_at 2.76
MAP2K5 mitogen-activated protein kinase kinase 5 204756_at 2.01
MMP2 matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72
kDa type IV collagenase)
201069_at 4.95
MMP9 matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92
kDa type IV collagenase)
203936_s_at 2.82
NOTCH2 notch 2 202443_x_at −4.95
PERP PERP, TP53 apoptosis effector 222392_x_at −3.73
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type
2 alpha
241905_at −7.36
PIK3C3 phosphatidylinositol 3-kinase, catalytic subunit type 3 232086_at 3.85
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit beta
217620_s_at −2.41
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit gamma
239294_at 4.24
PSENEN presenilin enhancer gamma secretase subunit 218302_at 2.92
RELA v-rel avian reticuloendotheliosis viral oncogene homolog A 201783_s_at –2.10
RRAS2 related RAS viral (r-ras) oncogene homolog 2 212589_at –4.12
SMAD2 SMAD family member 2 203076_s_at 2.50
SMAD3 SMAD family member 3 218284_at –4.13
TCF4 transcription factor 4 212385_at 2.92
TCF7L1 transcription factor 7-like 1 (T cell speciﬁc, HMG-box) 221016_s_at −2.41
TGFB2 transforming growth factor, beta 2 209909_s_at 8.74
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Validation of EMT markers with quantitative reverse
transcriptase PCR and immunohistochemistry
Two-step validation using quantitative reverse transcriptase
PCR (RT-qPCR) and immunohistochemistry conﬁrmed our
gene expression proﬁling data (Tables S3 and S4; Fig. 2a,
b). E-cadherin (CDH1) mRNA was downregulated in
AIPpos tumors (P= 0.004) compared to the normal pitui-
taries and sporadic GH adenomas (P= 0.001) (Fig. 2a). A
signiﬁcantly lower expression of E-cadherin was seen in
AIPpos tumors compared to normal pituitaries (P= 0.0008)
and to sporadic somatotrophinomas (P= 0.001) (Fig. 2b).
No signiﬁcant transcript level change was seen for CTNNB1
(cadherin-associated protein, beta-1) coding for β-catenin
(Fig. 2a); however, there was a signiﬁcant difference at the
protein level. Normal pituitary showed strong homogeneous
membranous β-catenin staining, whereas absent or weak
granular membranous beta-catenin expression was observed
in 40% of sporadic tumors and 83% of AIPpos tumors
(AIPpos vs. normal pituitary P= 0.01, AIPpos vs. sporadic
somatotrophinoma P= 0.04) (Fig. 2b). ESRP1 (epithelial
splicing regulatory protein 1), a novel molecular marker of
EMT, was signiﬁcantly downregulated in AIPpos tumors
compared to the normal pituitaries (P= 0.005) and sporadic
tumors (P= 0.0001) at the mRNA level (Fig. 2a). ESRP1
protein expression was signiﬁcantly decreased in AIPpos
tumors compared to normal pituitaries (P= 0.005) (Fig.
2b). PERP (TP53 apoptosis effector), an EMT-related gene,
was signiﬁcantly downregulated in AIPpos tumors both at
the RNA and protein level compared to normal pituitaries
(P= 0.01 and 0.03) and to sporadic somatotrophinomas (P
= 0.002 and 0.02) (Fig. 2a, b). The signiﬁcant transcrip-
tional downregulation of EPCAM (epithelial cell adhesion
molecule; CD326) was conﬁrmed in AIPpos tumors com-
pared to normal pituitaries (P= 0.01) and sporadic adeno-
mas (P= 0.004) (Fig. 2a). Upregulation of ZEB1 (zinc-
ﬁnger E-box binding homeobox 1), one of the master reg-
ulators of EMT, had higher mRNA expression (vs. normal
pituitary P= 0.005) and increased nuclear protein expres-
sion (vs. normal pituitary P= 0.006; vs. sporadic somato-
trophinomas P= 0.01) (Fig. 2a, b).
Macrophage secreted factors induce EMT-like
phenotype and enhance migration and invasion of
GH3-Aip-KD cells
AIPpos tumors contain a higher number of macrophages
and show an EMT signature corresponding to recent results
linking tumor-associated macrophages with EMT, which
might be critical for invasive behavior [15]. Therefore, we
investigated the impact of tumor-associated macrophages in
the invasive behavior of Aip-knockdown GH3 cells using
in vitro co-cultures. Freshly isolated rat bone marrow-
derived macrophages (conﬁrmed with macrophage markers
CD11b and CD68) grown in Roswell Park Memorial
Institute (RPMI) medium were stimulated with 320 nM
phorbol myristate acetate (PMA) for 24 h. Media was
replaced with RPMI which was collected at 72 h and then
used as macrophage-derived conditioned medium (MCM)
for the subsequent analysis (Fig. S3A and B). We used
lentiviral-transduced shRNA knockdown of Aip in the rat
pituitary somatomammotroph cell line GH3 (GH3-Aip-KD)
that show 80% reduced AIP protein expression (Fig. S3C).
In order to verify the functional effects of Aip knockdown,
we have used two different clones with 50% and 80% level
of Aip knockdown. Both the 50% and 80% knockdowns of
Aip show increased proliferation and colony formation
compared to non-targeting controls (GH3-NT) (Fig. S3D),
as previously shown in Aip knockdown [4, 16] or knockout
cells [17]. GH3-Aip-KD (80%) and GH3-NT cells were
incubated with MCM. A second set of cells following 72 h
MCM treatment were incubated with Dulbecco’s modiﬁed
Eagle’s medium (DMEM) for a further 72 h, to study if the
MCM-induced EMT-like changes could be reversed,
representing the mesenchymal-to-epithelial transition
process.
Cell morphology analysis by ImageJ demonstrated that
untreated GH3-NT and GH3-Aip-KD cells show no sig-
niﬁcant differences in cell size and shape (Fig. 3).
MCM-treated GH3-Aip-KD and GH3-NT cells both
underwent EMT-like changes with elongated, spindle-shape
mesenchymal morphology (Fig. 3a). However, these chan-
ges were signiﬁcantly more pronounced in GH3-Aip-KD
Table 1 (continued)
Symbol Entrez gene name Affymetrix Fold change
TWIST1 twist family bHLH transcription factor 1 213943_at −4.84
WNT4 wingless-type MMTV integration site family, member 4 208606_s_at 7.04
WNT5A wingless-type MMTV integration site family, member 5A 213425_at −4.70
ZEB1 zinc-ﬁnger E-box binding homeobox 1 210875_s_at 3.64
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cells as shown by cell shape analysis [18]: they have
approximately 62% increased cell surface area, 40% larger
perimeter and become 42% more elongated than the GH3-
NT cells (Fig. 3b–d). Roundness and circularity cell para-
meters between MCM-treated GH3-Aip-KD and GH3-NT
cells were not signiﬁcantly different. Cell solidity or
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stiffness are important features of cellular plasticity [19].
Solidity index was decreased for both cell lines following
MCM treatment, but GH3-Aip-KD cells had signiﬁcantly
lower solidity compared to GH3-NT cells, suggesting that
these cells are more deformable (Fig. 3g). This ﬂexibility is
required for migration/invasion through the extracellular
matrix and we observed this in the in vitro migration assay
where cells need to traverse 8 µm pores of transwell inserts
(see data below). After washing off MCM and 72 h treat-
ment with DMEM, both cell lines reverted back to a
rounded morphology, with circularity and roundness values
returning back to almost one, and showing increased
solidity, representing mesenchymal-to-epithelial transition
(Fig. 3e–g).
Analysis of EMT markers by immunoﬂuorescence ana-
lysis demonstrated that while untreated cells show mem-
branous E-cadherin and little cytoplasmic ZEB1 expression,
MCM-treated cells show lack of membranous E-cadherin
expression and a signiﬁcant increase in nuclear and cyto-
plasmic ZEB1 expression (Fig. 4a). Ingenuity pathway
analysis of AIPpos tumors transcriptome identiﬁed altered
actin cytoskeleton remodeling pathways. Actin staining of
GH3 cells showed that untreated cells have cortical actin
rings. After MCM treatment, GH3-NT cells show a granular
pattern of actin with less actin stress ﬁbers and actin spikes
whereas GH3-Aip-KD cells showed a mesenchymal phe-
notype with elongated morphology with prominent actin
stress ﬁbers and numerous actin spikes (Fig. 4a). In the
mesenchymal-to-epithelial transition state, cells re-organize
actin cytoskeleton and reverse their morphology. Western
blot analysis showed that expression of E-cadherin was
signiﬁcantly decreased (P= 0.006) whereas expression of
ZEB1 was increased in MCM-treated GH3-Aip-KD cells (P
= 0.001) compared to GH3-NT cells (Fig. 4b). These
results suggest that macrophage-derived soluble factors
could promote an EMT-like phenotype in rat pituitary GH3
cells.
Next, we assessed the functional consequences of EMT
to understand if MCM treatment was altering migration and
invasion capacity of GH3-Aip-KD and GH3-NT cells.
There was no difference in baseline migration between the
two cell lines. Incubation with MCM signiﬁcantly increased
cellular migration of GH3-Aip-KD cells compared to
untreated cells (Fig. S4). MCM treatment increased inva-
sion in both cell types, but more signiﬁcantly in GH3-Aip-
KD (P= 0.03) (Fig. 4c). These results indicate that acti-
vated macrophage-derived factors increase migration/inva-
sion of GH3-Aip-KD cells while GH3-NT shows no or little
response.
The effect of tumor-derived factors on macrophage
migration
As we found that macrophage-derived factors signiﬁcantly
altered the phenotypic and functional characteristics of
GH3-Aip-KD cells compared to the GH3-NT cells, we
tested effects of tumor-derived factors on macrophage
recruitment: GH3-Aip-KD cell-derived conditioned medium
was used as chemoattractant for migration of macrophages.
Increased macrophage migration was observed towards the
GH3-Aip-KD cell-derived medium compared to GH3-NT
cell-conditioned medium (Fig. S5A). These results
demonstrate that the GH3-Aip-KD cells release chemotactic
factors that might enable increased migration towards tumor
cells. Next, we explored human gene expression data to
search for potential chemotactic factors in AIPpos tumors
that could enhance macrophage migration. Our top candi-
date was chemokine C–C motif ligand 5 (CCL5). CCL5,
also known as RANTES (regulated upon activation, normal
T cell expressed and presumably secreted), a protein known
to be involved in recruitment of macrophages [20], was
signiﬁcantly upregulated (~6-fold) in AIPpos tumors com-
pared to normal pituitary and sporadic tumors. CCL5 is a
ligand for the CCR5 receptor expressed by macrophages.
We hypothesized that tumor-derived CCL5 increases mac-
rophage migration via activating CCR5 on macrophages.
To test this hypothesis ﬁrst we performed macrophage
chemotaxis assays using recombinant CCL5 as
Fig. 2 Validation of the selected EMT markers at the mRNA and
protein levels. a RT-qPCR validation of downregulated (CDH1,
CTNNB, ESRP1, PERP, and EPCAM) and upregulated (ZEB1) EMT
genes. RNA expression of the down- and upregulated genes in AIPpos
tumors (n= 6) compared to normal pituitaries (n= 5) and sporadic
GH tumors (n= 3) show conﬁrmation of the gene expression proﬁle
data. b Immunohistochemical analysis of downregulated (CDH1,
CTNNB, ESRP1, and PERP) and upregulated (ZEB1) EMT genes.
Protein expression in graphical form and with representative images in
AIPpos tumors compared to normal pituitaries and sporadic GH
tumors. E-cadherin: Normal pituitary cells are showing uniform strong
to moderate membranous staining. AIPpos GH tumor displays weak
diffuse cytoplasmic positivity without any membranous staining.
Sporadic GH adenoma shows membranous and granular cytoplasmic
positivity. Beta-catenin: Normal pituitary cells are showing strong to
moderate membranous immunoreactivity. AIPpos GH tumor displays
discontinuous cytoplasmic expression. Sporadic GH shows membra-
nous and granular cytoplasmic positivity. ESRP1: Normal pituitary
cells are showing strong cytoplasmic immunoreactivity. AIPpos GH
tumor shows weak cytoplasmic expression. Sporadic GH tumor shows
universal cytoplasmic and moderate to strong nuclear positivity.
PERP: Normal pituitary cells are showing strong granular cytoplasmic
positivity. AIPpos GH tumor shows cytoplasmic expression with the
nuclear atypia. Sporadic GH tumor shows granular cytoplasmic and
nuclear positivity of variable strength. ZEB1: Normal pituitary cells
are completely negative. AIPpos GH tumor exhibits uniform moderate
to strong positive nuclear staining. Sporadic GH tumor shows weak to
moderate nuclear staining in the majority of the tumor cells. Overall P
value for multiple comparison is shown in the left upper corner of each
graph, while signiﬁcance between groups are marked with *, <0.05,
**, <0.01, ***, <0.001 (Kruskal–Wallis test followed by Conover–
Inman test). All images are ×400 magniﬁcation and scale bar= 50 µm
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chemoattractant and then used the CCR5 inhibitor mar-
aviroc, an FDA-approved drug, to block their interaction.
Recombinant CCL5 increased activated macrophage
migration, and this was inhibited by maraviroc (Fig. S5B).
Subsequent experiments using GH3-Aip-KD-conditioned
media showed that maraviroc also inhibits macrophage
migration towards GH3-Aip-KD-conditioned media com-
pared to GH3-NT-conditioned media (Fig. 5a), indicating
the role of CCL5–CCR5 interaction in this phenomenon.
Furthermore, immunohistochemical analysis revealed
higher levels of CCL5 expression in AIPpos tumors than
normal pituitary (P= 0.001, Fig. 5b) and no difference
between sporadic tumors vs. normal pituitaries. CCL5
levels were elevated in GH3-Aip-KD condition media
compared to GH3-NT conditioned media (Fig. S5B). To
better understand the mechanism of macrophage
Fig. 3 Macrophage-conditioned media induce EMT-like phenotype in
GH3-Aip-KD cells. a Macrophage-conditioned media (MCM) induces
an EMT-like phenotype. Morphological changes in GH3-Aip-KD and
control GH3-NT (representative phase contrast images, top panels) and
quantiﬁcation of cell morphology (bottom panels). Untreated and
mesenchymal-to-epithelial transition state (replaced with DMEM)
GH3-Aip-KD and GH3-NT cells showed an epithelial cobblestone-like
morphology (phase contrast images: ﬁrst, third, fourth, and sixth
panels) whereas MCM-treated cells both GH3-NT and GH3-Aip-KD
become spindle shaped and show mesenchymal like morphology
(phase contrast images: second and ﬁfth panels). Untreated GH3-NT
and GH3-Aip-KD cells show no signiﬁcant differences in cell size and
shape. Morphology of the cells was quantiﬁed using six different
parameters (ImageJ). Around 100 cells from each condition were
evaluated. There was an increase in cell area (b) and perimeter (c) in
MCM-treated GH3-NT and GH3-Aip-KD cells, while, cells without
MCM treatment showed no difference. d Feret’s diameter (measure of
cell elongation) was signiﬁcantly higher in MCM-treated cells, indi-
cating more elongated cell shape. e, f Circularity and roundness (a
value closer to one is indicate more circular/rounded cells and close to
zero indicated an elongated shape): untreated and mesenchymal-to-
epithelial transition state cells of GH3-NT and GH3-Aip-KD showed
more circular and rounded shape than MCM-treated cells. g Solidity,
deﬁned as the ratio of cell area to the enclosing convex polygon area,
indicates the stiffness and deformability of cells, was decreased in both
GH3-NT and GH3-Aip-KD cells undergoing EMT. Overall P value for
multiple comparison is shown in the left upper corner of the graphs,
while signiﬁcance between groups are marked with *, <0.05, ***,
<0.001 (two-way ANOVA followed by Newman–Keuls multiple
comparison test). n= 3, performed in triplicates on three independent
days. Scale bar= 25 µm
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Fig. 4 Alterations of the EMT markers in GH3-NT and GH3-Aip-KD
cells. a Immunoﬂuorescence analysis of E-cadherin, ZEB1, and actin
in GH3-NT and GH3-Aip-KD cells with or without MCM at 72 h.
Untreated cells of GH3-NT and GH3-Aip-KD cells show membranous
localization of E-cadherin and low level of cytoplasmic ZEB1
expression, while MCM-treated cells show lack of membranous but
increased cytoplasmic E-cadherin expression and a signiﬁcant increase
in nuclear and cytoplasmic ZEB1 expression. After removal of MCM
and culturing cells in 10% DMEM for 72 h, the cells revert back to
their cobblestone-like morphology (mesenchymal-to-epithelial transi-
tion state), increased E-cadherin expression and localization as well as
reduced ZEB1 expression. Actin staining revealed that untreated cells
show cortical rings of actin. MCM-treated GH3-NT cells show gran-
ular pattern of actin with less actin stress ﬁbers while GH3-Aip-KD
cells showed prominent actin stress ﬁbers and numerous actin spikes
(inset). In contrast, in mesenchymal-to-epithelial transition state cells
are gradually return to the original state of their actin cytoskeleton
(×63 magniﬁcations). DAPI was used to stain the nuclei; the pictures
are representative of at least three experiments. b Immunoblotting
(densitometric analysis and representative images) suggested that E-
cadherin levels were signiﬁcantly decreased and ZEB1 signiﬁcantly
increased in MCM-treated GH3-Aip-KD cells compared to GH3-NT
cells. Overall P value for multiple comparison is shown, while sig-
niﬁcance between groups are marked with **, <0.01, ***, <0.001;
two-way ANOVA followed by Newman–Keuls multiple comparison
test. c Invasion assays showing that MCM treatment increases the
invasion of GH3-NT and GH3-Aip-KD cells. Bar charts show the
mean number of invading cells through the Matrigel-coated transwell
chambers measured after 72 h. Both GH3-NT and GH3-Aip-KD cells
show signiﬁcant increase in invasion compared to the untreated cells,
but was more signiﬁcant in GH3-Aip-KD cells. Representative pho-
tographs of invading cells are shown (×10), right panels. P values
indicated *, <0.05, **, <0.01; two-way ANOVA followed by New-
man–Keuls multiple comparison test. Data represent mean values of
three independent experiments
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recruitment via CCL5, we mined our gene expression pro-
ﬁle data to identify potential regulators of CCL5 in AIPpos
tumors. FLI1 (Friend leukemia virus integration site-1), a
transcription factor, was found to be four-fold upregulated
in AIPpos tumors compared to the normal pituitary. There
was a signiﬁcantly increased expression of FLI1 in AIPpos
tumors compared to either sporadic tumors (P= 0.003) or
normal pituitaries (P= 0.02) (Fig. 5c), therefore explaining
upregulated CCL5 [21].
Loss of AIP increases macrophage inﬁltrates in Aip-
knockout mice
To determine the relevance of our in vitro ﬁndings in vivo,
we evaluated the macrophage inﬁltrate in a pituitary-
speciﬁc Aip-knockout mice AipFlox/Flox;Hesx1Cre/+ who
develop GH-secreting pituitary tumors with disruption of
the reticulin network (detailed description of this animal
model will be reported separately). Based on our human
Fig. 5 The role of the CCL5 pathway in macrophage migration. a
Migration assays showing that macrophage migration was signiﬁcantly
reduced towards GH3-Aip-KD cell-derived conditioned media com-
pared to GH3-NT control cell-derived conditioned media. Macro-
phages were in vitro treated with maraviroc (200 nM) for 24 h and the
migration in response to GH3-Aip-KD-conditioned media and GH3-
NT conditioned media was evaluated. Cells were counted in nine
random ﬁelds and data are presented as mean ± SEM, n= 3. Graph
showing the percentage of the MVC-treated migrated macrophages
towards the GH3-NT and GH3-Aip-KD-conditioned medium relative
to the vehicle. V vehicle, MVC maraviroc. P values indicated ***,
<0.001; t-test. b Immunohistochemical analysis of CCL5 in normal
pituitary (NP, n= 11), AIP-mutation-positive somatotroph adenomas
(AIPpos GH, n= 12) and sporadic somatotroph adenomas (Sp GH,
n= 17). Graph showing that CCL5 is highly upregulated in AIPpos
tumors compared to the normal pituitary (left panel). Right panels
show the representative images of CCL5 staining. P values indicated
**, <0.01; one-way ANOVA with Bonferroni multiple comparison
test. All images are ×200 magniﬁcation and scale bar= 100 µm. c
Immunohistochemical analysis of FLI1 in normal pituitary (NP, n=
11), AIP-mutation-positive somatotroph adenomas (AIPpos GH, n=
12) and sporadic somatotroph adenomas (Sp GH, n= 17). Graph
showing that FLI1 is highly upregulated in AIPpos tumors compared
to the normal pituitary (left panel) and Sp GH tumors (left panel).
Right panels show the representative images of FLI1 staining. P values
indicated ***, <0.001; one-way ANOVA with Bonferroni multiple
comparison test. All images are ×200 magniﬁcation and scale bar=
100 µm
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data, we hypothesized that these animals will develop
pituitary adenomas with signiﬁcant macrophage inﬁltration.
Immunohistochemical analysis with F4/80 macrophage
marker from 15 months old homozygous AipFlox/Flox;
Hesx1Cre/+ mice pituitary glands showed a signiﬁcant
increase in the number of inﬁltrating macrophages as
compared to age-matched wild-type mice (P < 0.05) (Fig.
6), similar to AIP-mutation-positive human samples. These
results suggest that lack of AIP indeed leads to macrophage
inﬁltration in pituitary tumors.
Discussion
The tumor microenvironment plays a crucial role in the
growth and invasion of tumors [7, 8, 10], but this has not
been previously studied in aggressive pituitary tumors
associated with AIP mutations. Using gene expression
proﬁling of AIPpos human pituitary tumor samples, as well
as in vitro and in vivo models, we established that AIPpos
tumors have a unique microenvironment strikingly different
from that of sporadic pituitary tumors. We identiﬁed
increased number of tumor-associated macrophages in
AIPpos tumors compared to sporadic ones. Similar to
human AIPpos tumors, pituitary tumors from Aip-knockout
animals exhibit increased macrophage content, suggesting
that lack of AIP may be an important part of the molecular
pathway leading to macrophage migration in both mouse
and human pituitary tumors. Tumor-associated macro-
phages, typically with characteristics of activated macro-
phages, are an important component of the tumor
microenvironment [22, 23] and correlate with poor prog-
nosis in other tumor types [24]. Direct interactions between
macrophages and tumor cells have been documented by
multiphoton imaging [15, 25], and macrophages support
tumor cell migration and invasion by secreting matrix
degrading enzymes, such as plasminogen activator, cathe-
psin B and D, and matrix metalloproteases (MMP) 2 and 9
[26]. Indeed, MMP2 and MMP9, known to be associated
with cavernous sinus invasion [27], were upregulated in
AIPpos samples (Table 1). Tumor-associated macrophages
are linked with EMT [28, 29], which is present in AIP-
deﬁcient samples. MCM-treated GH3-Aip-KD cells
undergo numerous changes associated with EMT, such as
downregulation of E-cadherin and upregulation of ZEB1,
remodeling of the cytoskeleton, and increased motility.
However, there was no concomitant upregulation of clas-
sical mesenchymal markers, such as N-cadherin and
vimentin [30–32] in our microarray data, suggesting a
partial/incomplete EMT signature in AIPpos tumors. Partial
or incomplete EMT has also been observed in other solid
tumors [33]. Partial EMT was also found in some sporadic
GH tumors [34], but the protein expression of AIP was not
studied. As pituitary tumors locally invade but only very
rarely metastasize, the partial EMT phenotype would match
this clinical observation.
We saw increased expression of FOXP3+ T-reg cells in
AIPpos tumors compared to sporadic adenomas and normal
pituitary. FOXP3 is a speciﬁc T-reg marker that suppresses
anti-tumor immune responses. FOXP3+ T-reg cells are
associated with poor prognosis in various cancers [35, 36],
and with EMT type tumor cells. Interestingly, CCL5, the
Fig. 6 Loss of AIP increases macrophage inﬁltrates in the Aip-
knockout mice. Reticulin staining of wild type (WT) and homozygote
knockout (AipFlox/Flox;Hesx1Cre/+) pituitary tissue showing disrupted
reticulin network in the knockout animal. The bar graphs show the
increased number of macrophages in Aip-knockout mice compared to
the wild type. Representative images of macrophage inﬁltration in wild
type and homozygote Aip-knockout mice as determined by F4/
80 staining and quantiﬁed as the percentage of F4/80+ cells. Repre-
sentative immunostaining with F4/80 mouse macrophage marker (data
from n= 4 mice/genotype). Student’s t-test, *P < 0.05. Scale
bar= 50 µm
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cytokine we found overexpressed in AIPpos samples,
recruited T-reg cells in a mouse model of pancreatic cancer
[37]. Further studies will be needed to reveal the functional
role of FOXP3 in pituitary tumors and to see whether CCL5
is indeed involved in recruitment of T-reg cells in AIPpos
pituitary tumors.
Ingenuity pathway analysis of the differentially expres-
sed genes of AIPpos, sporadic GH, and normal pituitaries
highlighted the EMT pathway as one of the most sig-
niﬁcantly altered pathways in AIPpos tumors compared to
sporadic adenomas. EMT is a highly conserved cellular
process in which cells lose cell–cell contact and epithelial
characteristics, and gain a motile and invasive mesenchymal
phenotype, while mesenchymal-to-epithelial transition par-
ticipates in the establishment and stabilization of distant
metastases. In addition to their key role in development,
EMT and mesenchymal-to-epithelial transition are involved
with cancer progression. In AIPpos tumors we identiﬁed a
signiﬁcant number of altered EMT-associated genes,
including epithelial markers (CDH1, CTNNB1, ERSP1, and
EPCAM), a transcriptional (ZEB1) and a post-
transcriptional regulator (ESRP1), while there were no sta-
tistically signiﬁcant differences between sporadic adenomas
and normal pituitaries. Therefore, signiﬁcant disruption of
the EMT pathway in AIPpos tumors may cause their more
aggressive phenotype. Gene expression proﬁling and pro-
teomics studies [38–46] led to the identiﬁcation of genes
associated with invasion and aggressive behavior [42, 47].
Changes in EMT markers have been seen in sporadic
somatotroph adenomas with lower E-cadherin and ESRP1
expression [34, 48, 49]. Loss of ESRP1 in ~90% of AIPpos
cases indicates that ESRP1 may be an important regulator
of tumor invasiveness. GH itself has been suggested to
stimulate EMT [50–52]: autocrine/paracrine GH or treat-
ment with GH induces a complete EMT program and sig-
niﬁcantly up-regulates the classical mesenchymal markers
such as N-cadherin and vimentin in some cancers [52–54].
Although high levels of GH raises the possibility that they
play a role in the shift towards EMT in somatotroph tumors,
not all somatotroph tumors show that EMT and EMT
changes were not correlating with GH levels in sporadic
somatotrophinomas [34, 48]. Comparison of our AIPpos
tumor gene expression proﬁle with that of Aip-knockout
mouse embryonic ﬁbroblasts [55] showed only a modest
overlap. This could be explained by the different cell types
as cAMP is stimulating cell proliferation in some cell types
(e.g. adrenal and pituitary) while inhibits in others (e.g.
ﬁbroblasts and smooth muscle cells), and by the fact that
AIP tumor suppressor role is speciﬁc to the pituitary gland.
While incubation with MCM leads to an EMT-like
phenotype in both GH3-NT and GH3-Aip-KD cells, the
degree of change is signiﬁcantly different. Cell morphology
parameters, EMT markers, and actin changes were more
pronounced in GH3-Aip-KD cells, supporting the results on
increased migration since in order for cells to invade
through the extracellular matrix, ﬁlopodia/actin spikes
protrude, which are crucial for successful migration/inva-
sion. Media from macrophages stimulated GH3-Aip-KD
cells to increase migration and invasion, while this cell type
typically grown in complete medium do not show changes
in migration/invasion assays [56, 57].
Next, we investigated the role of tumor-derived factors
on macrophage recruitment. In the tumor microenvironment
tumor cells interact with stromal cells either by cell–cell
contacts or via paracrine signals. We hypothesized that
tumor-derived chemokines might direct macrophage hom-
ing to the tumor microenvironment. We found increased
expression of CCL5 in AIPpos tumors compared to the
normal pituitary. Interestingly, our in vitro model conﬁrmed
these ﬁndings as GH3-Aip-KD cells secrete more than twice
the amount of CCL5 into the media than GH3-NT cells.
Elevated levels of CCL5 are associated with tumor pro-
gression in different cancers [58]. CCL5 is involved in the
recruitment of monocytes, macrophages, and other inﬂam-
matory cells into inﬂammatory sites via activation of its
receptors CCR1, CCR3, CCR4, and mainly CCR5. The
CCL5/CCR5 axis plays an important role in the progression
of a number of solid tumors (breast, ovarian, gastric, cer-
vical, colorectal, and prostate) [59]. Maraviroc, a CCR5
antagonist initially approved for treatment of HIV infection,
inhibits chemotaxis of macrophage and monocyte-derived
dendritic cells towards CCL5 [60]. We demonstrated that
CCL5-dependent chemotaxis signiﬁcantly increased mac-
rophage migration towards the GH3-Aip-KD-conditioned
media compared to the GH3-NT-conditioned media and
disruption of this signaling by maraviroc resulted in 50%
reduction of macrophage migration. These results suggest
that cells lacking AIP secrete a signiﬁcant amount of CCL5,
which can increase macrophage migration toward these
cells and support macrophage migration into the tumor
microenvironment, at least partly, by CCL5/CCR5-depen-
dent chemotaxis. We also found upregulation of FLI1, the
transcriptional regulator of CCL5, at the gene and protein
level in AIPpos tumors [21]. Aberrant expression of FLI1 is
associated with hematological malignancies and solid
tumors [61–63]. Altered expression of FLI1 is also linked
with tumor aggressiveness [63] and poor prognosis [64]. In
our study, we have observed higher levels of FLI1
expression with the concomitant upregulation of CCL5 and
the increased number of macrophages in human AIPpos
tumors, supporting a crucial role for FLI1 and CCL5 in
macrophage recruitment. Based on these data, CCL5/CCR5
appears to be a key factor in AIP-mutation-related
tumorigenesis.
By identifying a novel regulatory pathway, our study
raised further interesting questions. Functional links
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between AIP, FLI1, and CCL5 or mechanism/s of how AIP
silencing stimulates FLI1 and subsequently CCL5 expres-
sion remain to be investigated. The role of AIP in immune-
related process is interesting, since AIP is a co-chaperone of
the aryl hydrocarbon receptor (AHR), a known immune
regulator of T helper Th17 cells [65, 66]. Low level of
AHR, which is found in AIPpos tumors [67], was found to
be associated with EMT via autophagy, as the autophagy
marker BNIP3 is inversely related to AHR protein levels
[68]. Indeed, we observed a signiﬁcant upregulation of
BNIP3 mRNA in AIPpos tumors.
Limitations of our study include the fact that we used a
rat cell line as no human somatotroph pituitary cell line
exists. The tumor microenvironment is complex of several
cell types which, in addition to macrophages, might affect
tumor cell behavior. Here we focused on macrophages, well
known to be associated with EMT, but other cell types may
also inﬂuence EMT in AIPpos tumors. We focused on pro-
inﬂammatory cytokine CCL5 although our microarray data
in human samples identiﬁed other signiﬁcantly differen-
tially expressed cytokines, such as TGFB, CCL4, and
osteopontin, which will be explored in future studies.
In summary, our results using a unique resource of
fresh frozen AIPpos tumors show an altered tumor
microenvironment of AIPpos tumors compared to spora-
dic pituitary adenomas, where tumor-derived factors, such
as CCL5, interact with macrophages resulting in increased
inﬁltration, EMT, and more aggressive phenotype. Fur-
thermore, as somatotroph tumors without AIP mutation
can also exhibit low AIP protein expression, our ﬁndings
could be relevant for a signiﬁcant proportion of patients
with somatotrophinomas. Immune inﬁltrates and EMT
signatures might also be useful as biomarkers to stratify
patient groups. Our results establish an important novel
crosstalk between tumor cells and the surrounding tumor




Fresh frozen AIPpos growth hormone-secreting adenomas
(n= 6) and sporadic GH-secreting adenoma (n= 4) (Table
S5) were obtained at transsphenoidal surgery. A part of each
sample was processed for routine histopathological and
immunohistochemical studies, and a part was snap-frozen.
Patients with sporadic tumors had no family history of
pituitary or other endocrine tumors. Autopsy pituitary
samples (n= 5) served as controls. For RT-qPCR validation
all the 15 samples used for microarray analysis were
included. For immunohistochemistry studies 8 additional
AIPpos formalin-ﬁxed parafﬁn-embedded tissue samples, as
well as pituitary tissue microarray consisting of 34 sporadic
somatotrophinomas and 13 normal pituitaries were used
(Table S6).
Gene expression analysis
Gene expression analysis was performed using Affymetrix
Human Gene Chip HG-U133 Plus 2.0 array (Affymetrix,
Santa Clara, CA, USA) (Supplementary material). Micro-
array data have been deposited to the National Centre for
Biotechnology Information’s Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo, accession number
GSE63357). Ingenuity Pathway Analysis, a web-based
application (www.ingenuity.com), was used to analyze
pathways and biological functions.
Quantitative reverse transcriptase PCR
The gene-speciﬁc primer/probe sets for CDH1, CTNNB1,
ESRP1, PERP, EPCAM, and ZEB1 were purchased from
Applied Biosystems (ABI, Foster City, CA, USA; Table
S7). For details of RT-qPCR methods please see Supple-
mentary Material.
Protein detection
Immunohistochemical staining and immunoblotting was
performed and scored as described in Supplementary
Material using primary antibodies listed in Table S8.
Cell line and in vitro functional study
We used rat pituitary cell line GH3 cells (obtained from
European Collection of Authenticated Cell Cultures at the
start of the project) and generated two stable knockdown
cell lines, a 50% and an 80% knockdown, and a non-
targeting control (GH3-NT) (Supplementary material). The
80% knockdown (GH3-Aip-KD) was used for the experi-
ments unless otherwise stated. Cells were cultured in high
glucose DMEM (Sigma, Gillingham, UK) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and 1%
penicillin and streptomycin. To collect GH3-conditioned
media for ELISA measurement of CCL5 levels, GH3-Aip-
KD and GH3-NT cells were seeded in six-well plates (2 ×
106), were grown for 24 h in 10% FBS DMEM and, fol-
lowing washing, incubated for 72 h in serum-free DMEM.
To collect GH3-conditioned media for macrophage migra-
tion assay, cells (5 × 106) were grown for 24 h in 10% FBS
DMEM and, following washing, incubated for 72 h in
serum-free DMEM for macrophage migration assays as
chemoattractant. Functional assays were repeated three
times and were performed at least in triplicate.
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Isolation and characterization of rat bone marrow-
derived macrophages
Macrophages were isolated from rat bone marrow and
cultures with granulocyte–macrophage colony-stimulating
factor in RPMI with 10% FBS. The expression of macro-
phage markers CD11b and CD68 was assessed by immu-
noﬂuorescence analysis (Supplementary material). At day 7
macrophages were treated with 320 nM PMA for 24 h and
then media was replaced with 10% RPMI. After 72 h this
media was collected and used as conditioned medium
(MCM) for the subsequent analysis.
MTS cell proliferation and colony formation assays were
performed as described previously [4]. Cell shape analysis,
invasion assay, generation of Aip knockout mice, and sta-
tistical analysis are described in Supplementary material.
Study approval
The study was approved by the Ethics Committee and
patients gave written informed consent.
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